Results 201 to 210 of about 20,131,715 (394)

Variants in AKR1D1 and Infant Mortality: Should Bile Acid Screening be a Routine Part of Newborn Screening?

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Biallelic pathogenic variants in AKR1D1 cause Δ4‐3‐oxosteroid 5β‐reductase deficiency, disrupt bile acid synthesis, and result in Congenital Bile Acid Synthesis defect type 2 (CBAS2). CBAS2 presents in infancy with cholestasis, coagulopathy, and failure to thrive.
Jade Hudson, Stephanie Hyunh, Bojana Rakic, Cornelius Boerkoel   +3 more
wiley   +1 more source

Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs

, 2017
Dustin B. Stephens, April M. Young, Jennifer R. Havens   +2 more
openalex   +2 more sources

Hepatitis C virus core protein enhances HIV‐1 replication in human macrophages through TLR2, JNK, and MEK1/2‐dependent upregulation of TNF‐α and IL‐6 [PDF]

, 2014
Gokul Swaminathan, Daniel Pascual, Germaine Rival, Renzo Perales‐Linares, Julio Martín‐García, Sonia Navas   +5 more
openalex   +1 more source

EASL Recommendations on Treatment of Hepatitis C 2016.

Journal of Hepatology, 2017
J. Pawlotsky, A. Aghemo, G. Dusheiko, X. Forns, M. Puoti, C. Sarrazin   +5 more
semanticscholar   +1 more source

Optimizing the dengue virus infection mouse model: Comparing different backgrounds and infection route for enhanced stability

Animal Models and Experimental Medicine, EarlyView.
Optimized dengue fever animal model: IFNAR−/− BALB/c mice with intraperitoneal injection. Background screening: Between IFNAR−/− (BALB/c, C57BL/6) and AG129 mice, IFNAR−/−BALB/c exhibited the most severe symptoms: (1) highest weight loss and clinical scores; (2) peak viremia (5.44 log10 RNA copies/mL, day 4); (3) significant organ damage (liver/brain ...
Dan Liao, Ming Zhong, Wenjiang Zheng, Zhendong Guo, Ye Zhou, Qiuhong Li, Lijuan Qiu, Liangwen Yu, Haishan Long, Geng Li   +9 more
wiley   +1 more source

The Patient-Provider Relationship Is Associated with Hepatitis C Treatment Eligibility: A Prospective Mixed-Methods Cohort Study

, 2016
Shari S. Rogal, Robert M. Arnold, Michael K. Chapko, Barbara Hanusa, Ada O. Youk, Galen E. Switzer, Mary Ann Sevick, Nichole K. Bayliss, Carolyn L. Zook, Alexis P. Chidi, D. Scott Obrosky, Susan Zickmund   +11 more
openalex   +2 more sources

Optimal management of patients with chronic hepatitis C and comorbidities [PDF]

, 2014
V. Boccaccio, Savino Bruno
openalex   +1 more source

Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

Hepatology, 2015
Aasld Idsa Hcv Guidance Panel
semanticscholar   +1 more source

Radiation emergency medical countermeasures: Current formulary, identified gaps, and future approaches

Animal Models and Experimental Medicine, EarlyView.
Current radiation medical countermeasures primarily focus on hematopoietic acute radiation syndrome (H‐ARS) using agents like granulocyte colony‐stimulating factor (G‐CSF), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), and romiplostim, alongside treatments for internal contamination (Prussian blue, diethylenetriamine pentaacetate [DTPA ...
Wen‐Bing Ma, Rong‐Hua Yin, Guang‐Ming Ren, Yin Zhang, Li‐Juan Li, Wei Liu, Ting Chen, Wei Zhou, Mian Zu, Rong‐Ling Yin, Xin‐Di Shi, Lei Wang, Xiao‐Ming Yang   +12 more
wiley   +1 more source

Injecting Drug Users' Understanding of Hepatitis C [PDF]

Most Australians who have hepatitis C contracted the virus through the shared use of drug injecting equipment. Further, the prevalence and incidence of hepatitis C virus (HCV) are high among Australian injecting drug users (IDUs), around 50 to 60 percent
Black, E, Day, C, Dolan, K, O'Brien, S, Thetford, Clare   +4 more
core